Vanderbilt University Invests $254,000 in Progyny, Inc. (NASDAQ:PGNY)

Vanderbilt University bought a new stake in Progyny, Inc. (NASDAQ:PGNY) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 14,730 shares of the company’s stock, valued at approximately $254,000.

Several other institutional investors and hedge funds have also bought and sold shares of PGNY. GAMMA Investing LLC lifted its stake in Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after acquiring an additional 1,246 shares during the last quarter. Creative Planning lifted its stake in Progyny by 13.8% in the 2nd quarter. Creative Planning now owns 10,564 shares of the company’s stock valued at $302,000 after purchasing an additional 1,283 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after purchasing an additional 1,526 shares during the last quarter. Cetera Trust Company N.A grew its holdings in Progyny by 30.0% during the third quarter. Cetera Trust Company N.A now owns 7,210 shares of the company’s stock worth $121,000 after purchasing an additional 1,665 shares during the period. Finally, KBC Group NV increased its position in Progyny by 84.6% during the fourth quarter. KBC Group NV now owns 4,669 shares of the company’s stock worth $81,000 after buying an additional 2,140 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Insider Activity

In other news, Chairman David J. Schlanger acquired 150,000 shares of Progyny stock in a transaction that occurred on Thursday, December 26th. The stock was bought at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the transaction, the chairman now owns 228,269 shares in the company, valued at $3,350,988.92. The trade was a 191.65 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Peter Anevski purchased 209,500 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was acquired at an average price of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the transaction, the chief executive officer now directly owns 441,463 shares of the company’s stock, valued at approximately $6,392,384.24. This trade represents a 90.32 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on PGNY. Bank of America cut their price objective on Progyny from $22.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Canaccord Genuity Group cut their price target on Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a report on Wednesday, November 13th. JPMorgan Chase & Co. upped their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Barclays lowered their target price on Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, Truist Financial restated a “hold” rating and set a $19.00 target price (down previously from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Nine investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Progyny currently has an average rating of “Hold” and an average price target of $25.50.

Progyny Stock Performance

NASDAQ PGNY opened at $22.72 on Thursday. The company has a fifty day moving average of $18.08 and a 200-day moving average of $19.05. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $42.08. The company has a market capitalization of $1.93 billion, a P/E ratio of 39.17, a P/E/G ratio of 2.32 and a beta of 1.34.

Progyny (NASDAQ:PGNY) last issued its earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.26). The firm had revenue of $286.63 million during the quarter, compared to analysts’ expectations of $296.85 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The firm’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.16 earnings per share. As a group, analysts forecast that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.